Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 40.02 as of 2026-10-06T17:36:58.361Z.
Consensus retrieved: 2026-10-06T12:54:36.205Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:36:58.361Z.
Quote observation: 2026-10-06T17:35:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a2615b192eb7b3c63221ad5ea08173b8616d5e3346e126019b52367b3931f2a6
Forward PE Ratio (40.02) = Dated Quote Price ($84.57) / Consensus Forward EPS ($2.11)
FORWARD PE RATIO
40.02
SECTOR MEDIAN · HEALTHCARE
19.70
median of 183 covered companies
CURRENT VS SECTOR MEDIAN
+103.15%
vs the sector median at left
IRadimed Corporation
Market Cap
$1.08B
Forward PE Ratio
40.02
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| IRadimed Corporation (IRMD) | $1.08B | 40.02 |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.09B | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A |
| Replimune Group, Inc. (REPL)vs › | $1.10B | N/A |
| STAAR Surgical Company (STAA)vs › | $1.11B | 76.58 |
| OPKO Health, Inc. (OPK)vs › | $1.11B | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | N/A |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.12B | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.12B | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | N/A |
Trailing P/E
47.3
reported TTM EPS
Forward P/E
40.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.11 implies +17.9% EPS growth vs the reported trailing $1.79.
At the dated quote price of $84.57, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.11 | $2.03 – $2.19 | 2 | 40.0x |
| 2027-12-31 | $2.45 | $2.40 – $2.53 | 2 | 34.5x |
| 2028-12-31 | $2.71 | $2.71 – $2.72 | 2 | 31.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
